The *TGFB1* Functional Polymorphism rs1800469 and Susceptibility to Atrial Fibrillation in Two Chinese Han Populations

Weixing Zheng1*, Chenghui Yan2*, Xiaohu Wang3*, Zhurong Luo1, Fengping Chen1, Yuhui Yang1, Donglin Liu1, Xiaobo Gai1, Jianping Hou1, Mingfang Huang1*

1 Department of Cardiology, Fuzhou General Hospital, Fujian Medical University, Fuzhou, China, 2 Department of Cardiology, Shenyang General Hospital, Shenyang, China, 3 Department of Cardiology, Fujian Provincial Hospital, Fuzhou, China

Abstract

Transforming growth factor-β1 (TGF-β1) is related to the degree of atrial fibrosis and plays critical roles in the induction and perpetuation of atrial fibrillation (AF). To investigate the association of the common promoter polymorphism rs1800469 in the TGF-β1 gene (*TGFB1*) with the risk of AF in Chinese Han population, we carried out a case-control study of two hospital-based independent populations: Southeast Chinese population (581 patients with AF and 723 controls), and Northeast Chinese population (308 AF patients and 292 controls). Two hundred and seventy-eight cases of AF were lone AF and 334 cases of AF were diagnosed as paroxysmal AF. In both populations, AF patients had larger left atrial diameters than the controls did. The rs1800469 genotypes in the *TGFB1* gene were determined by polymerase chain reaction-restriction fragment length polymorphism. The genotype and allele frequencies of rs1800469 were not different between AF patients and controls of the Southeast Chinese population, Northeast Chinese population, and total Study Population. After adjustment for age, sex, hypertension and LAD, there was no association between the rs1800469 polymorphism and the risk of AF under the dominant, recessive and additive genetic models. Similar results were obtained from subanalysis of the lone and paroxysmal AF subgroups. Our results do not support the role of the *TGFB1* rs1800469 functional gene variant in the development of AF in the Chinese Han population.

Introduction

Atrial fibrillation (AF), the most common clinical arrhythmia, is responsible for substantial morbidity and mortality in the general population [1,2]. AF is associated with changes in cardiac structure and electrical properties known as structural and electrical remodeling. Atrial fibrosis, a hallmark of arrhythmogenic structural remodeling, can lead to increased nonuniform anisotropy in conduction and has been found to be an important substrate for the induction and perpetuation of AF [3–6].

In the heart, fibrosis is thought to be partially mediated by transforming growth factor-β1 (TGF-β1), a potent stimulator of collagen-producing cardiomyofibroblasts [3]. There is growing evidence that TGF-β1 can induce atrial fibrosis and play a major role in AF. Using microarray analysis, Barth et al [7] demonstrated upregulated expression of mRNA in the atria of patients with permanent AF. In patients who underwent both open heart surgery for valvar heart disease and the surgical maze procedure for persistent AF, preoperative plasma TGF-β1 levels were related to the degree of atrial fibrosis and could be used to predict the recurrence of AF at the 1-year follow-up after the surgical maze procedure [8]. In patients with non-paroxysmal AF, the plasma TGF-β1 level is an independent predictor of AF recurrence after catheter ablation [9]. In human AF, Gramley et al noted upregulated TGF-β1 expression at the mRNA and protein levels in atrial tissue at different stages of fibrogenesis [10].

In canine models, heart failure led to increased atrial TGF-β1 expression and atrial fibrosis, and inhibition of TGF-β1...
expression prevented atrial fibrosis and development the AF substrate [11]. In a transgenic mouse model over-expressing constitutively active TGFB1, there was selective atrial interstitial fibrosis, while ventricular histology was normal [12–14]. This increase in atrial fibrosis was shown to correspond to an increase in conduction heterogeneity and AF vulnerability [13,14]. In another study by the same group, the drug pirfenidone was used to target TGFB1 expression [15]. Similar results were observed in an experimental model of heart failure, from which increased TGFB1 expression and atrial fibrosis were reported [11,15], and pirfenidone treatment resulted in a significant reduction of TGFB1 expression and atrial fibrosis. This reduction in atrial fibrosis also corresponded to a decrease in conduction abnormalities and in AF vulnerability [15].

A number of studies have attempted to determine whether naturally occurring single-nucleotide polymorphisms (SNPs) in the TGFB1 gene (TGFB1; gene map locus: chromosome 19q13.1-13.3) affect TGFB1 expression and TGFB1 production. For example, A C-to-T SNP at position -509 relative to the first major transcription start site (-509C>T SNP; rs1800469) was found to be differentially related with transcription factor binding to the TGFB1 promoter, transcriptional activity of TGFB1, and TGFB1 plasma concentration [16,17]. The -868T>C SNP (rs1982073), which gives rise to an amino acid substitution at position 10 (Leu10Pro), was reported to influence steady-state concentrations of TGFB1 mRNA in peripheral blood mononuclear cells and serum TGFB1 levels [18,19]. Other SNPs, such as variants at positions -800 (rs1800468), codon 25 (rs1800471, Arg25Pro), and codon 263 (rs1800472, Thr263Ile), were also reported to be functional and can affect TGFB1 production and/or activation[16,18–23]. It is reasonable to believe that one of these functional genetic variants is associated with the risk of AF. To the best of our knowledge, none of these SNPs has ever been studied in relation to the risk of AF in a general population.

We hypothesized that functional genetic variations in TGFB1 might contribute to the susceptibility to AF. A high degree of linkage disequilibrium has been observed between rs1800469 and rs1982073 in the Chinese Han population [24–26], whereas the rs1800468, rs1800471, and rs1800472 are extremely rare in the unrelated Chinese individuals [24,26–28]. We focused on rs1800469 as a tagging SNP, to explore its relationship with the risk of AF in two Chinese Han populations in a case-control study.

Patients and Methods

Ethics Statement

The Ethics Committees of Fuzhou General Hospital and Shenyang General Hospital approved this study. All subjects provided informed written consent in accordance with the Declaration of Helsinki.

Populations

The subjects in this study were unrelated Chinese Han from the Southeast Chinese population were patients from Fuzhou General Hospital. We enrolled 581 patients with AF and 723 controls consecutively from June 2007 to April 2010. Subjects from the Northeast Chinese population were patients from Shenyang General Hospital. We enrolled 308 AF patients and 292 controls consecutively from December 2008 to April 2010.

Inclusion and Exclusion Criteria

For cases, i.e., AF patients, the inclusion criteria were signs and symptoms of AF confirmed by a cardiologist based on at least one 12-lead resting electrocardiogram (ECG). Controls were enrolled from the same ward during the same period as the cases and verified as being free of AF by a cardiologist, based on ECG or medical files. The controls were individually matched with cases according to the following criteria: sex, age (±5 years), area of residence (from the same province), and presence of hypertension.

Subjects with signs of moderate to severe congestive heart failure greater than New York Heart Association class II, any significant valvular disease greater than grade II on a scale of I–IV, dilated or hypertrophic cardiomyopathy, congenital heart disease or a history of myocarditis were excluded from the study to avoid the role of disease-related atrial remodeling for the genesis of secondary AF. Further exclusion criteria were any severe concomitant pathologic condition such as hyperthyroidism, acute pneumonia or chronic lung disease, and neoplastic, renal and liver diseases. Subjects with palpitations without ECG documentation were excluded from both the case and control groups. Patients with pacemakers or cardioverter-defibrillator implantation before the occurrence of AF were also excluded.

Protocol

AF was defined as the replacement of sinus P waves by rapid oscillations or fibrillatory waves of varied in size, shape, and timing that were associated with an irregular ventricular response when atrioventricular conduction was intact. The presence of AF was determined from history, followed by serial ECG or ambulatory electrocardiographic monitoring. Lone AF was defined as AF occurring in individuals aged <65 years without hypertension, overt structural heart disease, or thyroid dysfunction, as determined by clinical examination, ECG, echocardiography, and thyroid function tests. Paroxysmal AF was defined as AF lasting >30 s that terminated spontaneously. The AF was classified as persistent when it lasted >7 days and required either pharmacological therapy or electrical cardioversion for termination. AF that was completely refractory to cardioversion or that was allowed to continue was classified as permanent [29]. Hypertension was defined according to the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure criteria: systolic blood pressure equal to or over 140 mm Hg and/or diastolic blood pressure equal to or over 90 mm Hg (average of two measurements) or being on treatment with antihypertensive therapy [30]. Current smoking status was determined at the time of blood collection. Dyslipidemia was defined according to the Third Report of the National
were randomly selected for direct sequencing, and the results in independent samples detect the -509C>T polymorphism in the promoter, the primers expressed as mean ± SD or median and interquartile ranges as anti-coagulated peripheral blood using a commercially available kit (Beijing CoWin Biotech Co., Ltd., Beijing, China) as described previously and stored at −20 °C [33]. The genotype of the -509C>T (rs1800469) polymorphism of the TGFB1 gene was determined by polymerase chain reaction (PCR)-restriction fragment length polymorphism. In briefly, to detect the -509C>T polymorphism in the promoter, the primers 5'-CCC GCC TCC ATT TCC AGG TG-3' and 5'-GGT CAC CAG AGA AAG AGG AC-3' were used to PCR-amplify a fragment of the TGFB1 gene [34]. The PCR was performed in a 25-μl reaction containing 25-50 ng genomic DNA, 1x PCR buffer, 2.0 mmol/l MgCl₂, 200 μmol/l dNTP, 10 pmol of each primer, and 0.5 U of Ex Taq DNA polymerase (TaKaRa, Dalian, China). Amplification conditions were as follows: an initial activation step of 94°C for 5 min followed by 35 cycles of denaturation at 94°C for 30 s, annealing at 60°C for 30 s, extension at 72°C for 1 min, and a final extension step at 72°C for 10 min.

The resultant 808-bp fragment was digested at 37°C for overnight using restriction enzyme Eco81I (TaKaRa, Dalian, China). Eco81I does not digest the T allele, but digest the C allele into 617-bp and 191-bp fragments.

Standard precautions to avoid contamination during PCR were taken. A negative control serum was included in each reaction to ensure specificity. Two researchers, who were blinded to the clinical data performed the genotyping independently. If there was any discordance between their findings, a third researcher would perform the genotyping and determine whether it was necessary to repeat the assay. Additionally, about 10% of the samples were randomly selected to perform the repeat assays, the results were 100% concordant. Furthermore, approximately 3% of the samples were randomly selected for direct sequencing, and the results were 100% concordant.

DNA Extraction and Genotyping
DNA was extracted from ethylene diamine tetraacetic acid anti-coagulated peripheral blood using a commercially available kit (Beijing CoWin Biotech Co., Ltd., Beijing, China) as described previously and stored at −20 °C [33].

The Kolmogorov–Smirnov test was performed to evaluate the normality of data distribution. Continuous variables were expressed as mean ± SD or median and interquartile ranges as appropriate. Statistical significance of differences in quantitative variables was tested using the Student’s independent samples t-test and analysis of covariance or the nonparametric Wilcoxon test for normally or non-normally distributed variables, respectively. Categorical data are presented as frequencies (percentage). Differences between categorical variables, genotype/allele frequencies, and Hardy-Weinberg equilibrium were tested by the χ² test or Fisher’s exact test. The association between the rs1800469 polymorphism and AF was assessed using logistic regression analysis under dominant, recessive, and additive genetic models. Variables such as age, sex, hypertension, and LAD were included in the multivariate model. We determined the odds ratio (OR) and 95% confidence interval. Analysis was performed using SPSS for Windows Version 11.5 (SPSS Inc., Chicago, IL, USA). Two-sided P-values < 0.05 were considered significant.

The software package Quanto 2.4 (http://hydra.usc.edu/gxe) was used for power calculations. Based on the minor allele frequency of 0.442 for rs1800469 as reported in the haplotype map of the CHB population, and assuming a dominant model, the study had >80% statistical power to detect an association (at P < 0.05) with an OR of 1.40, indicating a very low risk of a false-negative result.

Results
There were 889 patients with AF and 1015 controls. Two hundred and seventy-eight cases of AF were lone AF (146 and 132 cases in the Southeast and Northeast Chinese population, respectively) and 334 cases of AF were diagnosed as paroxysmal AF (192 and 142 cases in the Southeast and Northeast Chinese population, respectively). As expected, AF patients in both study populations had larger LAD than the controls did (Southeast and Northeast Chinese cases vs. controls: 4.2 cm vs. 3.7 cm; and 4.1 cm vs. 3.6 cm, respectively, both P < 0.001). However, no significant differences were observed between the cases and controls with regard to age, sex distribution, and cardiovascular risk factors, such as hypertension, diabetes, dyslipidemia, and smoking habits in both study populations. Moreover, the distribution of other clinical characteristics such as height, weight and body mass index, LVEF and LVEDD were not significantly different in both the cases and controls (Table 1).

The demographic and clinical characteristics of the study populations are reported in Table S1. There were significant differences in the years of AF, age, height, weight, body mass index, and LVEF between the Southeast and Northeast Chinese population. Significant differences were also found in sex ratio, the ratio of paroxysmal, permanent, and lone AF, diabetes mellitus, smoking, and use of antiarrhythmic medication between the two populations. There were no significant differences in the ratio of hypertension, dyslipidemia, persistent AF, LAD, LVEDD, and use of anticoagulant and β-blocker medication between the two populations.

The genotype distribution and allele frequencies of the rs1800469 polymorphism in the TGFB1 gene are listed in Tables 2-4. The genotype distributions of the SNP in all groups were consistent with those expected for samples in Hardy-Weinberg equilibrium. Despite their geographical distance (Southeast and Northeast China), there was no difference in genotype distribution of the SNP between the two populations in control groups. The respective genotype and allele frequencies of the rs1800469 polymorphism were not different for women and men in both populations.
Genotype distribution of the SNP between groups: for AF patients: global χ² = 1.079, df=2, P=0.583; for lone AF patients: global χ²=0.275, df=2, P=0.617; for paroxysmal AF patients: global χ²=1.079, df=2, P=0.583.

Atrial fibrillation (AF), hypertension, body mass index (BMI), left atrial dimension (LAD), left ventricular end-diastolic diameter (LVEDD), left ventricular ejection fraction (LVEF), and age are related to AF susceptibility in the Chinese Han population. We did not observe a significant difference in the genotype and allele frequencies of the rs1800469 polymorphism between the Southeast Chinese population, Northeast Chinese population, and the total study populations (Table 5). We further investigated whether the SNP was associated with lone AF and paroxysmal AF. There were no significant differences in the genotype and allele frequencies of the rs1800469 and the risk of AF between lone AF patients and controls, and between paroxysmal AF patients and controls in the Southeast Chinese population, Northeast Chinese population and total study populations (Tables 2-5).

We investigated the association between the SNP genotype and other risk factors for AF. Table S2 lists the demographic data, clinical parameters, cardiovascular risk factors, and echocardiographic features of the three genotypes. None of these parameters was significantly different among the three groups.

**Discussion**

To the best of our knowledge, this is the first study to examine the association between the rs1800469 polymorphism of the TGFβ1 gene and susceptibility to AF. We did not observe a significant difference in the genotype or allele frequencies of this SNP between AF patients and controls in the Southeast Chinese population, Northeast Chinese population and total study populations. Emerging data supports the premise that lone AF and paroxysmal AF are mechanistically different from non-lone and non-paroxysmal AF phenotypes [35,36]. Thus, we performed a subanalysis of the AF population. There were similar findings for the lone AF and paroxysmal AF subgroups. Our results suggest that rs1800469 of the TGFβ1 gene is not related to AF susceptibility in the Chinese Han population.

The TGFβ1 gene was analyzed as a candidate gene for AF because of its functional relation with the modulation of tissue fibrosis, upregulated expression in experimental and human AF [7–11,15,37], as well as selective atrial fibrosis and increased AF inducibility in cardiac-specific overexpression of constitutively active TGFβ1 in mice [12–14]. Promoter polymorphisms and non-synonymous variants are generally considered likely causal variants themselves and not merely

**Table 2. Genotype distribution and allele frequencies of**

| Genotypes and alleles | Controls (n = 723) | Cases (n = 581) | OR (95% CI) Reference | OR (95% CI) Reference | OR (95% CI) Reference |
|-----------------------|-------------------|----------------|----------------------|----------------------|----------------------|
|                       |                   |                | P                    |                     |                     |
| CC                    | 196 (27.1)        | 159 (27.4)     | Reference            | 39 (26.7)           | Reference            |
| CT                    | 356 (49.2)        | 301 (51.8)     | 1.04 (0.80-1.35)     | 0.755 (75.1)        | 1.06 (0.69-1.62)     |
| TT                    | 171 (23.7)        | 121 (20.8)     | 0.87 (0.64-1.19)     | 0.392 (32.1)        | 0.94 (0.56-1.57)     |
| HWE                   | 0.706             | 0.328          | 0.719                | 0.277               |          |
| C                     | 748 (51.7)        | 619 (53.3)     | Reference            | 153 (52.4)          | Reference            |
| T                     | 698 (48.3)        | 543 (46.7)     | 0.94 (0.81-1.10)     | 0.433 (139.7)       | 0.97 (0.89-1.17)     |

Genotype distribution and allelic status were analyzed with the χ² value test. Values are given as n (%).

**Table 1. Clinical characteristics of cases and controls.**

| Characteristics | Southeast Chinese population | Northeast Chinese population | P |
|-----------------|-----------------------------|-----------------------------|---|
| Sample size, n  | 581                         | 723                         | P |
| Age-range, years| 21-92                       | 35-93                       | 32-90 | 40-92 | P |
| Age, years      | 70.6 ± 11.1                 | 70.6 ± 10.2                 | 0.992 | 66.4 ± 11.2 | 66.0 ± 10.1 | 0.671 |
| Gender (male/ female), n | 361/220 | 444/279 | 0.789 | 212/96 | 197/95 | 0.720 |
| Hypertension, n (%) | 249 (42.9) | 296 (41.0) | 0.486 | 142 (46.1) | 132 (45.2) | 0.825 |
| Diabetes mellitus, n (%) | 100 (17.2) | 106 (14.7) | 0.209 | 65 (21.1) | 69 (23.6) | 0.458 |
| Dyslipidemia, n (%) | 110 (19.8) | 151 (20.9) | 0.381 | 70 (22.7) | 59 (20.2) | 0.452 |
| Smoking, n (%)   | 130 (22.4)                  | 187 (25.9)                 | 0.144 | 109 (35.4) | 92 (31.5) | 0.314 |
| Height, cm       | 165.5 ± 7.4                 | 164.8 ± 7.2               | 0.103 | 168.1 ± 5.9 | 167.6 ± 5.5 | 0.242 |
| Weight, kg       | 67.0 ± 9.5                  | 66.2 ± 9.8                 | 0.189 | 70.7 ± 6.0 | 70.4 ± 7.1 | 0.617 |
| BMI, kg/m²       | 24.5 ± 2.7                  | 24.3 ± 2.9                 | 0.295 | 25.0 ± 2.4 | 25.1 ± 2.2 | 0.701 |
| LAD, cm          | 4.2 (3.8-4.7)               | 3.7 (3.3-4.1)              | 0.001 | 4.1 (3.6-4.6) | 3.6 (3.3-4.0) | 0.001 |
| LVEF, %          | 61 (58-64)                  | 62 (59-64)                 | 0.069 | 59 (56-64) | 60 (57-64) | 0.155 |
| LVEDD, cm        | 4.7 (4.4-5.1)               | 4.7 (4.5-5.0)              | 0.332 | 4.7 (4.4-5.1) | 4.7 (4.3-4.9) | 0.216 |

Values are mean±SD, n (%), or median (interquartile range).

BMI indicates body mass index; LAD, left atrial dimension; LVEF, left ventricular ejection fraction; LVEDD, left ventricular end-diastolic diameter.

doi: 10.1371/journal.pone.0083033.t001

doi: 10.1371/journal.pone.0083033.t002
the present study, we examined the association between AF indicates atrial fibrillation; M1, dominant model; M2, recessive model; M3, additive model; OR, odds ratio; CI, confidence interval.

Genotype distribution of the SNP between groups: for AF patients: global $\chi^2$=1.370, df=2, $P=0.504$; for lone AF patients: global $\chi^2$=1.484, df=2, $P=0.476$; for paroxysmal AF patients: global $\chi^2$=1.191, df=2, $P=0.581$; AF, atrial fibrillation; HWE, P-value for exact Hardy–Weinberg equilibrium test; OR, odds ratio; CI, confidence interval.

doi: 10.1371/journal.pone.0083033.t003

Table 3. Genotype distribution and allele frequencies of -509C>T polymorphism in the Northeast Chinese population.

| Genotypes and alleles | Controls (n = 292) | Cases (n = 308) | OR (95% CI) P | M1 OR (95% CI) P | M2 OR (95% CI) P | M3 OR (95% CI) P |
|-----------------------|-------------------|----------------|---------------|----------------|----------------|----------------|
| CC                    | 88 (30.1)         | 83 (26.9)      | Reference     | 39 (29.6)      | Reference     | 38 (28.8)      |
| CT                    | 152 (52.1)        | 160 (52.0)     | 1.12 (0.77-1.62) 0.564 63 (47.7) 0.94 (0.58-1.51) 0.784 73 (51.4) 0.90 (0.56-1.44) 0.659 |
| TT                    | 52 (17.8)         | 65 (21.1)      | 1.33 (0.83-2.13) 0.242 30 (22.7) 1.30 (0.72-2.34) 0.378 31 (21.8) 0.72 (0.40-1.30) 0.279 |
| HWE                   | 0.329             | 0.456          | 0.638          | 0.715          |
| C                     | 326 (56.2)        | 326 (52.9)     | Reference     | 141 (53.4)     | Reference     | 149 (52.5)     |
| T                     | 256 (43.8)        | 290 (47.1)     | 1.14 (0.91-1.43) 0.260 123 (46.6) 1.12 (0.84-1.50) 0.455 135 (47.5) 0.86 (0.65-1.15) 0.304 |

Genotype and allelic status were analyzed with the $\chi^2$ value test. Values are given as n (%).

doi: 10.1371/journal.pone.0083033.t004

Table 4. Genotype distribution and allele frequencies of -509C>T polymorphism in total study population.

| Genotypes and alleles | Controls (n = 1015) | Cases (n = 889) | OR (95% CI) P | M1 OR (95% CI) P | M2 OR (95% CI) P | M3 OR (95% CI) P |
|-----------------------|---------------------|----------------|---------------|----------------|----------------|----------------|
| CC                    | 284 (27.9)          | 242 (27.2)     | Reference     | 78 (28.1)      | Reference     | 97 (29.0)      |
| CT                    | 508 (50.1)          | 461 (51.9)     | 1.07 (0.86-1.32) 0.562 138 (49.6) 0.99 (0.72-1.35) 0.945 161 (48.2) 1.08 (0.61-1.44) 0.614 |
| TT                    | 223 (22.0)          | 186 (20.9)     | 0.98 (0.76-1.27) 0.872 62 (22.3) 1.01 (0.70-1.48) 0.949 76 (22.8) 1.00 (0.71-1.42) 0.990 |
| HWE                   | 0.883               | 0.219          | 0.948          | 0.557          |
| C                     | 1076 (53.0)         | 945 (53.1)     | Reference     | 294 (52.9)     | Reference     | 355 (53.1)     |
| T                     | 954 (47.0)          | 833 (46.9)     | 0.99 (0.88-1.13) 0.929 262 (47.1) 1.01 (0.83-1.21) 0.958 313 (46.9) 1.01 (0.84-1.20) 0.950 |

Genotype and allelic status were analyzed with the $\chi^2$ value test. Values are given as n (%).

doi: 10.1371/journal.pone.0083033.t005

Table 5. Association between the -509C>T polymorphism with atrial fibrillation.

|                  | Controls, n | Cases, n | M1 OR (95% CI) | M2 OR (95% CI) | M3 OR (95% CI) | P |
|------------------|-------------|----------|----------------|----------------|----------------|---|
| Southeast Chinese population | 723 | 581 | 0.98 (0.73-1.30) | 0.864 | 0.95 (0.73-1.24) | 0.701 | 1.06 (0.84-1.34) | 0.630 |
| Northeast Chinese population | 292 | 308 | 1.27 (0.82-1.97) | 0.277 | 0.75 (0.51-1.10) | 0.143 | 1.08 (0.77-1.53) | 0.644 |
| Total study population | 1015 | 889 | 1.03 (0.81-1.30) | 0.831 | 0.89 (0.72-1.11) | 0.298 | 1.08 (0.89-1.31) | 0.453 |
| Lone AF           | 1015 | 278 | 1.00 (0.83-1.22) | 0.964 | 0.98 (0.74-1.24) | 0.737 | 1.05 (0.83-1.32) | 0.690 |
| Paroxysmal AF     | 1015 | 334 | 1.06 (0.90-1.24) | 0.498 | 0.97 (0.73-1.30) | 0.852 | 1.03 (0.85-1.24) | 0.782 |

A Adjusted for age, gender, hypertension and Left atrial dimension. AF indicates atrial fibrillation; M1, dominant model; M2, recessive model; M3, additive model; OR, odds ratio; CI, confidence interval.

doi: 10.1371/journal.pone.0083033.t006

markers associated by linkage disequilibrium to causal variants in their vicinity. Several such variants in the TGFB1 gene with possible functional significance have been reported [16–23]. In the present study, we examined the association between rs1800469 of the TGFB1 gene and susceptibility to AF. Cases and controls were matched by geographic regions, and the two study populations comprised a single Chinese Han ethnicity. There was no difference in genotype distribution of rs1800469 between controls in the two populations, rendering the risk of stratification of the populations for the polymorphism unlikely. The minor allele frequency of rs1800469 was 0.442, similar to that previously reported in normal Chinese Han populations [24–27,38]. Assuming an additive genetic model, our sample size had >80% power to detect an association with an OR for disease of >1.2. Under a dominant or a recessive model, association with an OR of >1.4 was detected. The power of the study was thus sufficient to detect associations of modest magnitude. We found no significant association between the
common SNP rs1800469 of the *TGFB1* gene and the risk of AF. The rs1800473 polymorphism (868T>C, Leu10Pro), in strong linkage disequilibrium with the rs1800469 polymorphism in the Chinese Han population [24–26], is theoretically not related to susceptibility to AF. Our results were consistent with that of Wang et al. [39] who noted no significant association between the rs1800473 and the risk of AF in subjects with essential hypertension. These results indicated that the effect of the functional SNP effect did not significantly increase the risk of AF. Although we were unable to examine TGFB1 gene expression, there is evidence that the SNP involved in the present candidate gene study has functional significance, and likely alters the promoter-reporter activity and plasma concentration of TGFB1 [16,17]. However, the function of the TGFB1 protein may be too complex for a single variant effect, and the true relationship between TGFB1 and AF may lie in gene-gene or gene-environment interactions.

Recent genome-wide association studies of AF have focused on a few chromosomal regions with strong signals [40–43]. Despite such studies yielding promising results, a large percentage of the heritability of AF remains unexplained [44]. A growing number of researchers are turning to rare genetic changes with strong effects as important contributors [45,46]. The variants at positions -800, of codon 25 or 263 of the TGFB1 gene are rare variants in unrelated Chinese Han individuals [24,26–28]. The rs1800468 polymorphism is located in a partial putative cyclic adenosine monophosphate response element-binding protein consensus site and may alter transcription [16]. The rs1800471 polymorphism was found to be related to TGFB1 production in peripheral blood leukocytes [19–22], and functional analysis of rs1800472 with a luciferase reporter assay demonstrated that the protective variant I263 of the TGFB1 gene is more active than the T263 variant [23]. These rare SNPs may be related with the risk of AF. However, our sample did not have sufficient power to detect the effect of any rare variants with a frequency of < 0.05. The rapid development of next-generation sequencing allows reliable detection of associations between rare variants and AF in larger populations [47,48]. Future research involving large-scale studies is needed to extend the present findings by detecting associations between these rare variants and the risk of AF in independent populations.

The present study has several limitations. First, different geographical and racial backgrounds of the individuals studied can affect the results of an association study. Therefore, our findings need to be confirmed in other populations. Moreover, potential selection bias might have occurred because control subjects selection in our study was hospital-based. Lastly, we cannot exclude the presence of asymptomatic AF in the controls even though we conducted an accurate interview weighted to symptoms related to dysrhythmias.

In summary, our results did not indicate a direct influence of the *TGFB1* rs1800469 functional gene polymorphism in increased risk of AF in two Chinese Han populations. Further studies are required to elucidate the role of this gene in the predisposition to AF.

**Supporting Information**

**Table S1. Clinical Characteristics of the study population.**

**Table S2. Clinical features in study subjects by TGFB1 -509C>T genotype.**

**Acknowledgements**

We are indebted to all patients for their invaluable collaboration. We also thank Xi Meng and Jinge Ouyang for their help in recruiting the patients.

**Author Contributions**

Conceived and designed the experiments: WZ CY XW ZL MH. Performed the experiments: WZ CY XW ZL FC YY DL MH. Analyzed the data: CY XW ZL FC JH XG YY DL MH. Contributed reagents/materials/analysis tools: WZ CY XW ZL FC JH XG YY DL MH. Wrote the manuscript: WZ CY XW ZL MH.

**References**

1. Nattel S (2002) New ideas about atrial fibrillation 50 years on. Nature 415: 219-226. doi:10.1038/415227a1. PubMed: 11805846.
2. Heeringa J, van der Kuip DA, Hofman A, Kors JA, van Herpen G et al. (2006) Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 27: 949-953. PubMed: 16527828.
3. Akikawa-Uchida Y, Ashizawa N, Ohtsuru A, Seto S, Tsukazaki T et al. (2002) Norepinephrine enhances fibrosis mediated by TGFB-beta in cardiac fibroblasts. Hypertension 40: 148-154. doi:10.1161/1051-1140.00025443.61926.12. PubMed: 12154105.
4. Li D, Fareh S, Leung TK, Nattel S (1999) Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. Circulation 100: 87-95. doi:10.1161/1051-1140.00025443.61926.12. PubMed: 10393686.
5. Li D, Shinagawa K, Pang L, Leung TK, Cardin S et al. (2001) Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation 104: 2606-2614. doi:10.1161/hc4601.099402. PubMed: 11714658.
6. Aldhoon B, Melonenški V, Peichl P, Kautzner J (2010) New insights into mechanisms of atrial fibrillation. Physiol Res 59: 1-12. PubMed: 19249911.
7. Barth AS, Merk S, Arnoldi E, Zwermann L, Kloc P et al. (2005) Reprogramming of the human atrial transcriptome in permanent atrial fibrillation: expression of a ventricular-like genomic signature. Circ Res 96: 1022-1029. doi:10.1161/01.RES.0000165480.82737.33. PubMed: 15817885.
8. On YK, Jeon ES, Lee SY, Shin DH, Choi JO et al. (2009) Plasma transforming growth factor beta1 as a biochemical marker to predict the persistence of atrial fibrillation after the surgical maze procedure. J Thorac Cardiovasc Surg 137: 1515-1520. doi:10.1016/j.jtcs.2008.10.022. PubMed: 19464473.
9. Wu CH, Hu YF, Chou CY, Lin YJ, Chang SL et al. (2012) Transforming growth factor-beta(1) level and outcome after catheter ablation for nonparoxysmal atrial fibrillation. Heart Rhythm 9: 323-328. doi:10.1016/j.hrthm.2012.02.015. PubMed: 22372671.
10. Gramley F, Lorenzen J, Koellensperger E, Kettering K, Weiss C et al. (2010) Atrial fibrosis and atrial fibrillation: the role of the TGFB-beta1
27. Funder WD, Unsworth S, O'Donnell K, Dunbar R, Cooper S et al. (2000) Association of a T29--C polymorphism of the transforming growth factor-beta1 gene with genetic susceptibility to myocardial infarction in hypertensive subjects. J Biomed Sci 17: 23. doi:10.1186/1423-0127-17-23.

28. Liu DS, Li XO, Ying BW, Chen L, Wang T et al. (2010) Effects of single nucleotide polymorphisms 869 T/C and 915 G/C in the exon 12 of transforming growth factor-beta1 gene on chronic obstructive pulmonary disease susceptibility in Chinese. Chin Med J (Engl) 123: 390-394. PubMed: 20193474.

29. Vittinghoff E, Frieden V, Ryden LE, Alpert NR, Cannom DS, Crijs HJ et al. (2001) ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Subcommittee on Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology. Circulation 104: 2118-2150. PubMed: 11673357.

30. Cifkova R, Erdine S, Fagard R, Farsang C, Heagerty AM et al. (2003) Practice guidelines for primary care physicians: 2003 ESH/ESC hypertension guidelines. J Hypertens 21: 1779-1786. doi:10.1097/00004872-200310000-00001. PubMed: 14508180.

31. Warnick GR, Myers GL, Cooper GR, Rifai N (2002) Impact of the third cholesterol report from the adult treatment panel of the national cholesterol education program on the clinical laboratory. Clin Chem 48: 11-17. PubMed: 11751533.

32. Gudbjartsson DF, Albert KS, Ott CN, Buse J, Deprez R et al. (2003) Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 26: 3160-3167. doi:10.2337/diacare.26.11.3160. PubMed: 14578255.

33. Gudbjartsson DF, Holm H, Gretarsdottir S, Thorleifsson G, Walters GB et al. (2007) Variants conferring risk of atrial fibrillation on chromosome 2p and 6q. Am J Hum Genet 81: 95-107. doi:10.1093/hmg/ddl279. PubMed: 17335844.

34. Gudbjartsson DF, Arnar DO, Helgadottir A, Gretarsdottir S, Holm H et al. (2010) Genome-wide association analysis identifies 17 new common variants conferring risk of atrial fibrillation in European-Americans and East Asian. http://dx.doi.org/10.1001/circulationaha.110.945709. PubMed: 20855661.

35. Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA et al. (2009) Common versus rare variants in disease susceptibility: the likely contribution of rare alleles. PLoS Genet 5: e1000528. doi:10.1371/journal.pgen.1000528. PubMed: 19683608.

36. Polyakova V, Miyagawa S, Szalay Z, Risteli J, Kostin S (2008) Atrial extracellular matrix remodelling in patients with atrial fibrillation. J Cell Mol Med 12: 189-208. PubMed: 18194448.

37. Manolio TA, Photo D, Chambert K, Dallongeville J, Hu Y et al. (2009) Common and rare variants in five千万 traits and risk of cardiovascular disease. N Engl J Med 360: 1509-1522. doi:10.1056/nejmoa0807141. PubMed: 19477045.
47. Mardis ER (2008) Next-generation DNA sequencing methods. Annu
Rev Genomics Hum Genet 9: 387-402. doi:10.1146/annurev.genom.
9.081307.164359. PubMed: 18576944.

48. Shendure J, Ji H (2008) Next-generation DNA sequencing. Nat
Biotechnol 26: 1135-1145. doi:10.1038/nbt1486. PubMed: 19840087.